---
title: "ROIV.US (ROIV.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ROIV.US/news.md"
symbol: "ROIV.US"
name: "ROIV.US"
parent: "https://longbridge.com/en/quote/ROIV.US.md"
datetime: "2026-05-20T10:07:25.095Z"
locales:
  - [en](https://longbridge.com/en/quote/ROIV.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ROIV.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ROIV.US/news.md)
---

# ROIV.US (ROIV.US) — Related News

### [Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.23, Implies 28% Upside](https://longbridge.com/en/news/287004510.md)
*2026-05-20T04:20:04.000Z*
> Roivant Sciences Ltd.'s stock price target has been raised to $36.23, indicating a potential upside of 28%. The average 

### [Pre-Market Earnings Report for May 20, 2026 :  ADI, TJX, LOW, TGT, ROIV, HAS, GDS, VFC, BZ, IMVT, ZIM, ARCO](https://longbridge.com/en/news/286960671.md)
*2026-05-19T20:10:17.000Z*
> On May 20, 2026, several companies are set to report earnings, including ADI, TJX, LOW, TGT, ROIV, HAS, GDS, and VFC. AD

### [Top Biotech Insider Makes Bold Multi-Million Dollar Stock Move](https://longbridge.com/en/news/283754673.md)
*2026-04-23T02:04:13.000Z*
> On April 22, 2026, Eric Venker, President and CEO of Immunovant, sold 200,000 shares of Roivant Sciences (ROIV) for $5.9

### [Roivant Sciences CEO Sold Shares Worth Over $8.4M](https://longbridge.com/en/news/283408332.md)
*2026-04-20T22:30:02.000Z*
> Matthew Gline, CEO of Roivant Sciences, sold Common Shares worth $8.4 million at an average price of $29.16 per share. A

### [Roivant Sciences (ROIV) Gets a Buy from J.P. Morgan](https://longbridge.com/en/news/283225952.md)
*2026-04-18T12:17:31.000Z*
> J.P. Morgan analyst Brian Cheng has maintained a Buy rating on Roivant Sciences (ROIV) with a price target of $35.00, wh

### [A Look At Roivant Sciences (ROIV) Valuation As Analyst Upgrades And Brepocitinib Progress Lift Sentiment](https://longbridge.com/en/news/282490838.md)
*2026-04-13T05:40:41.000Z*
> Roivant Sciences (ROIV) has gained attention due to positive analyst ratings and progress in its brepocitinib program. T

### [Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)?](https://longbridge.com/en/news/282411993.md)
*2026-04-11T09:40:38.000Z*
> Roivant Sciences has initiated a Phase 2b/3 trial of brepocitinib for lichen planopilaris and released mixed results fro

### [Bioharvest Sciences Earnings Call Highlights Growth Momentum](https://longbridge.com/en/news/281722300.md)
*2026-04-06T00:28:40.000Z*
> Bioharvest Sciences Earnings Call Highlights Growth Momentum

### [ROIS establishes itself as Global CDMO with US Expansion](https://longbridge.com/en/news/281562237.md)
*2026-04-02T18:07:07.000Z*
> ROIS, the CDMO arm of ROVI, has acquired a state-of-the-art injectable manufacturing site in Phoenix, Arizona, from Bris